This study is part of the NIH’s Helping to End Addiction Long-term (HEAL) initiative to speed scientific solutions to understand the basis of pain and enhance clinical pain management. The NINDS has a need for biological therapeutics assay development subject matter expert (SME) consultants to provide technical recommendations and advice that will support the translational development of novel therapeutics (Biologics) for NIH drug discovery and development programs. The support included in this contract will cover bioassay development and/or qualification/validation for a variety of biologics including but not limited to: monoclonal antibodies, peptide therapeutics, viral vector therapeutics (e.g., AAV, lentiviruses, etc.), nucleic acid and cell-based therapeutics, proteins, or other biological therapeutic modalities. Preferably, consultants should have significant expertise supporting assay development for more than one biological therapeutic modality (e.g., monoclonals, peptides, ASOs and viral vectors).